Почетна › Рак јајника › Masachuset
Kliničke studije za Рак јајника u državi Masachuset
70 studija za Рак јајника traži učesnike na lokacijama u državi Masachuset.
Gradovi u državi Masachuset
Zvanični tekst studije (na engleskom)
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 13. 11. 2026. · NCT06964009Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- и још 1
Тражи се учесникФаза 2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT05564377A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Lahey Clinic ( Site 0042), Burlington
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT07743164Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
- Tufts Medical Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT07718854Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Baystate Medical Center, Springfield
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06580314A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0104, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 9. 11. 2026. · NCT04516447Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 6. 11. 2026. · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Beth Israel Deaconess Medical Center, Boston
- Baystate Medical Center, Springfield
Тражи се учесник
Узраст од 35 до 50 · Жене · Ажурирано 6. 11. 2026. · NCT04251052A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Lahey Hospital & Medical Center ( Site 0031), Burlington
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 5. 11. 2026. · NCT07776691A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Massachusetts Chan Medical School, Worcester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213804Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07059884A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Dana Farber Cancer Institute (DFCI), Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0221 - Tufts Medical Center - PPDS, Boston
- Site 0104 - Dana Farber Cancer Institute, Boston
- Site 0307 - Lahey Hospital and Medical Center, Burlington
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 30. 10. 2026. · NCT05128825A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 28. 10. 2026. · NCT06819007A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT04657068A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 19. 10. 2026. · NCT03854110Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06239194Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- Dana Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 15. 10. 2026. · NCT05287451A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- UMass Memorial Medical Center - Belmont Street /ID# 278628, Worcester
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 13. 10. 2026. · NCT07059845Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05123482Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06993844Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
Тражи се учесникФаза 1/2
Узраст од 18 до 130 · Оба пола · Ажурирано 5. 10. 2026. · NCT05417594Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
Тражи се учесникФаза 1/2
Узраст од 18 до 130 · Оба пола · Ажурирано 5. 10. 2026. · NCT05797168A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT05877599Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Жене · Ажурирано 25. 9. 2026. · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Жене · Ажурирано 24. 9. 2026. · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 21. 9. 2026. · NCT05983432A Study of Isoquercetin in People With Ovarian Cancer
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT07303894A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Massachusetts General Hospital, Boston
- Umass Memorial Medical Center, Inc., Worcester
Тражи се учесникФаза 2
Узраст од 18 до 99 · Жене · Ажурирано 15. 9. 2026. · NCT07023627Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.